No Data
Orient: DNA methylation assists in the diagnosis and treatment of endometrial cancer. Pay attention to companies related to the Industry Chain.
DNA methylation has been confirmed to have auxiliary diagnostic value for early endometrial cancer. With its advantages of being earlier and less invasive, it has become one of the methods for early auxiliary diagnosis of various cancers.
Guolian's investment strategy for the CSI SWS Health Care index in 2025: Look at space for incremental growth and at structure for existing assets.
Looking ahead to the CSI SWS Health Care index in 2025, from the perspective of incremental growth, attention should be paid to the long-term development of three major areas: medical insurance, self-paying, and overseas expansion; from the perspective of existing growth, attention should be paid to the essence of medicine and Medical.
Amoy Diagnostics (300685.SZ): repurchased a total of 1.17% of shares.
Gelonghui, January 3丨Amoy Diagnostics (300685.SZ) announced that as of December 31, 2024, the company implemented the repurchase of 4,676,240 shares through a dedicated securities account via centralized bidding trade, accounting for 1.17% of the company’s current total equity. The highest Fill Price for repurchased shares was 23.80 yuan/share, the lowest Fill Price was 17.20 yuan/share, and the total amount paid was 86,072,544.00 yuan (excluding transaction fees).
Guolian: It is the right time for domestic medical instruments to go global. Focus on leading companies with first-mover advantages in going abroad.
Domestic medical instruments have advantages in production, manufacturing, and upgrades, laying a foundation for products to go global, and the Global medical instruments market has vast potential.
Amoy Diagnostics (300685): Leading the way in companion diagnostics, embracing the era of precise cancer treatment.
Amoy Diagnostics is an internationally leading enterprise in precision Medical molecular diagnostics. Amoy Diagnostics focuses on tumor gene testing, concentrating on companion diagnostics, relying on robust bioinformatics algorithms, and establishing reagents, Software, and supporting instruments while also providing testing services and drug clinical research.
Amoy Diagnostics (300685.SZ): has obtained the invention patent certificate.
Gelonghui, on December 13th, announced that Amoy Diagnostics (300685.SZ) recently received an invention patent certificate issued by the Japan Patent Office. The patent is titled "Probe primer set for detecting gene mutations in myeloid leukemia based on high-throughput sequencing and its application," with patent number 7591097, classified as an invention. The patent rights are valid for twenty years from the date of application, and the patent holder is the company.